CXCL9 and EASIX for Prediction of Acute Graft Versus Host Disease

CXC-chemokine Ligand 9 (CXCL9) and Endothelial Activation and Stress Index (EASIX) for Prediction of Acute Graft Versus Host Disease

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05718791

Enrollment

100

Registered

2023-02-08

Start date

2023-05-10

Completion date

2027-12-30

Last updated

2026-05-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

GVHD,Acute

Brief summary

The prediction of severe acute GVHD before it occurs is of high importance for ensuing clinical decisions and overall success of allogeneic SCT. The key immunologic signatures associated with clinical outcomes after different graft versus host disease prophylaxis methods or peripheral blood stem cell transplant are largely unknown.

Interventions

DIAGNOSTIC_TESTblood sample

blood sample to check CXCL9 and EASIX at day 28 post stem cell transplant

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Inclusion criteria

* Patients \>18 year old admitted for allo SCT PB for malignant disease.

Design outcomes

Primary

Measure	Time frame	Description
predictors of acute GVHD	CXCL9 combined with EASIX calculated at day 28 +/- 2 post SCT can be used as predictors of acute GVHD by day 100.	CXCL9 combined with EASIX can be used as predictors of acute GVHD

Countries

United States

Contacts

CONTACTshatha farhan, MD

sfarhan1@hfhs.org3137133910

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 2, 2026